Research programme: IPL99 series - Inflazyme

Drug Profile

Research programme: IPL99 series - Inflazyme

Alternative Names: IPL99 series research programme - Inflazyme

Latest Information Update: 26 Feb 2004

Price : $50

At a glance

  • Originator Inflazyme Pharmaceuticals
  • Class Small molecules
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Inflammation

Most Recent Events

  • 26 Feb 2004 This programme is still in active development - 2nd Annual BioPartnering North America conference (BPN-2004)
  • 27 Feb 2003 Preclinical trials in Inflammation in Canada (unspecified route)
  • 27 Feb 2003 The IPL99 programme is available for partnering (
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top